Suppression of the hypothalamic–pituitary–gonadal axis by TAK-385 (relugolix), a novel, investigational, orally active, small molecule gonadotropin-releasing hormone (GnRH) antagonist: Studies in human GnRH receptor knock-in mice

2014 ◽  
Vol 723 ◽  
pp. 167-174 ◽  
Author(s):  
Daisuke Nakata ◽  
Tsuneo Masaki ◽  
Akira Tanaka ◽  
Mie Yoshimatsu ◽  
Yumiko Akinaga ◽  
...  
2006 ◽  
Vol 49 (11) ◽  
pp. 3362-3367 ◽  
Author(s):  
Haitao Li ◽  
Kenna L. Anderes ◽  
Eugenia A. Kraynov ◽  
David R. Luthin ◽  
Quyen-Quyen Do ◽  
...  

2006 ◽  
Vol 49 (19) ◽  
pp. 5849-5849 ◽  
Author(s):  
Haitao Li ◽  
Kenna L. Anderes ◽  
Eugenia A. Kraynov ◽  
David R. Luthin ◽  
Quyen-Quyen Do ◽  
...  

2009 ◽  
Vol 92 (3) ◽  
pp. S113
Author(s):  
A. Tanaka ◽  
D. Nakata ◽  
M. Yoshimatsu ◽  
Y. Akinaga ◽  
K. Miwa ◽  
...  

MedChemComm ◽  
2017 ◽  
Vol 8 (10) ◽  
pp. 1965-1969 ◽  
Author(s):  
Richard Fjellaksel ◽  
Marc Boomgaren ◽  
Rune Sundset ◽  
Ira H. Haraldsen ◽  
Jørn H. Hansen ◽  
...  

In this communication, we report the synthesis and characterization of a library of small molecule antagonists of the human gonadotropin releasing hormone receptor based upon the 2-(4-tert-butylphenyl)-4-piperazinyl-benzimidazole scaffold via Cu-catalysed azide alkyne cycloaddition.


2002 ◽  
Vol 12 (23) ◽  
pp. 3467-3470 ◽  
Author(s):  
David R. Luthin ◽  
Yufeng Hong ◽  
Ved P. Pathak ◽  
Genevieve Paderes ◽  
Karen D. Nared-Hood ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document